- Report
- January 2023
- 131 Pages
Global
From €5285EUR$5,500USD£4,518GBP
- Report
- September 2019
- 399 Pages
Global
From €1321EUR$1,375USD£1,130GBP
€2642EUR$2,750USD£2,259GBP
- Report
- February 2019
- 148 Pages
Global
From €1321EUR$1,375USD£1,130GBP
€2642EUR$2,750USD£2,259GBP
- Report
- August 2018
- 211 Pages
Global
From €1321EUR$1,375USD£1,130GBP
€2642EUR$2,750USD£2,259GBP
- Report
- August 2018
- 15 Pages
Global
From €601EUR$625USD£513GBP
€1201EUR$1,250USD£1,027GBP
- Report
- October 2019
Global
From €2690EUR$2,800USD£2,300GBP
- Report
- April 2019
- 1200 Pages
Global
From €2690EUR$2,800USD£2,300GBP
- Report
- May 2024
- 93 Pages
From €2883EUR$3,000USD£2,464GBP
- Report
- December 2021
- 100 Pages
Global
From €5717EUR$5,950USD£4,888GBP
From €3363EUR$3,500USD£2,875GBP
- Report
- November 2023
- 78 Pages
Germany
From €3363EUR$3,500USD£2,875GBP
- Report
- November 2023
- 78 Pages
France
From €3363EUR$3,500USD£2,875GBP
- Report
- March 2023
- 116 Pages
Global
From €4708EUR$4,900USD£4,025GBP
- Report
- December 2022
- 115 Pages
Global
From €4708EUR$4,900USD£4,025GBP
- Report
- September 2022
- 94 Pages
Global
From €4756EUR$4,950USD£4,066GBP
- Report
- September 2022
- 62 Pages
Global
From €4756EUR$4,950USD£4,066GBP
- Report
- June 2021
- 77 Pages
Global
From €4756EUR$4,950USD£4,066GBP
- Report
- March 2019
- 88 Pages
Global
From €2883EUR$3,000USD£2,464GBP
- Report
- January 2022
- 200 Pages
Global
From €7206EUR$7,500USD£6,161GBP
From €2402EUR$2,500USD£2,054GBP
The CAS9 market is a subset of the genomics industry that focuses on the development and use of the CRISPR-Cas9 gene-editing technology. This technology is used to modify the genetic code of living organisms, allowing for the manipulation of genes and the potential to create new treatments for diseases. CAS9 is a powerful tool for researchers, allowing them to make precise changes to the genetic code of organisms.
The CAS9 market is growing rapidly, with many companies investing in the technology and its applications. Companies such as Editas Medicine, Intellia Therapeutics, CRISPR Therapeutics, and Caribou Biosciences are leading the way in developing and commercializing the technology. Other companies such as Horizon Discovery, Synthego, and Twist Bioscience are also investing in the CAS9 market, providing tools and services to researchers. Show Less Read more